Highest development stage: Preclinical

Development dropped

Gram-positive activity

Reason dropped: When comparing linezolid and PNU-177553, there in vitro, there was cross resistance additionally testing against 23 strains of M. pneumoniae, linezolid's MIC ranged 1 - >32mg/ml compared with this compound's 4 - >32mg/ml

Additional information: 1. Schaadt R, Perricone S, Hester J, et al. In vitro antibacterial activity of PNU-177553, a novel antibacterial agent. 41st-ICAAC 2001;226-227 2. Watts JL, Salmon SA, Klein LK, et al. In vitro activity of PNU-177553 against atypical respiratory pathogens. 41st-ICAAC 2001;227